NW Bio appoints vet Rosskamp as CEO of German subsidiary

Friday, September 21, 2012 01:24 PM

Northwest Biotherapeutics, a biotech developing DCVaxR personalized immune therapies for cancer, has appointed former pharmaceutical industry executive Dr. Gunter Rosskamp as the CEO of the company's German subsidiary, Northwest Biotherapeutics, Gmbh.

Rosskamp brings extensive experience as a senior manager in the pharmaceutical sector.  He previously served as head of central nervous system (CNS) therapeutics at Schering (now part of Bayer) with responsibility for R&D and global marketing and sales of CNS products. He subsequently served as head of strategic business development at Schering, Rosskamp also served as vice president of life sciences and chemicals at the German Industrial Investment Council (IIC). More recently, he served as CEO of three biotech companies, including a company developing treatments for inflammatory and immune disorders, and two companies developing cell therapy products. 

Rosskamp succeeds Dr. Bernhard Faber, who served as the interim start-up CEO of Northwest Biotherapeutics' German subsidiary.

Share:          
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs